Market reactionShares rose 14% on Nov 6.
Equillium is a clinical-stage company developing EQ504, an oral colon-targeted drug that acts on the aryl hydrocarbon receptor, for ulcerative colitis; it is not approved.
Equillium's case rests on EQ504, an investigational oral, colon-targeted AhR modulator for ulcerative colitis. Healthy-volunteer dosing has begun in Australia, with Phase 1 proof-of-mechanism data anticipated in Q2 2027. Supportive results would enable a placebo-controlled patient study in the second half of 2027. Cash was $57.2 million as of June 30, 2026; an additional $20 million milestone closing is expected, not confirmed received. Management expects cash with those proceeds to fund currently planned operations into 2029.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: The Phase 1 shows EQ504 acts in the gut
Does EQ504 show tolerable dosing and convincing localized gut activity in healthy volunteers?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
EQ504 dosing begins; gut activity data expected in Q2 2027
Private placement financing closed
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung and respiratory diseases, Liver and digestive diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.